Makers Laboratories EBITDA

Mitä Makers Laboratories tekee? Makers Laboratories Ltd. generates revenue through the manufacturing and marketing of pharmaceutical products across various therapeutic segments. The company's product portfolio includes formulation brands such as Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (anti-cough range), and Exylin (Amoxycillin range). These brands target general health needs and are distributed through the Inspira retail packs division, which covers categories like acid regulatory, anthelmintics, anti-allergics, and anti-hypertensives. The Experia bulk packs division supplies bulk pharmaceutical products including amoxycillin 250 mg capsules and chloroquine phosphate 250 mg tablets to healthcare providers and pharmacies. The company's primary customers are healthcare providers and pharmacies that purchase its formulation brands and bulk packs for resale or direct patient use. The Inspira retail packs division serves retail consumers seeking over-the-counter medications for common ailments, while the Experia bulk packs division caters to institutional buyers needing bulk quantities for distribution. Makers Laboratories Ltd. focuses on the pharmaceuticals segment, offering products that address diverse health conditions through its established brand portfolio. Revenue streams are derived from both retail and bulk sales, with formulation brands driving consumer-facing sales and bulk packs supporting institutional distribution. The company's product range spans multiple therapeutic areas, ensuring consistent demand across different healthcare segments. By maintaining a diverse portfolio of branded and bulk pharmaceutical products, Makers Laboratories Ltd. effectively targets both end consumers and healthcare institutions within the Indian pharmaceutical market. Makers Laboratories on yksi Eurpooliin suosituimmista yhtiöistä.